Datasets:
Inabia-AI
/
continued-pretraining

Dataset card Data Studio Files
xet
 Community
1
text
stringlengths
1
5.46k
7.12. Mode of Payment; Offsets ....................................................................................................... 62
7.13. Withholding Taxes ................................................................................................................... 62
7.14. Indirect Taxes .......................................................................................................................... 63
7.15. Financial Records .................................................................................................................... 63
7.16. Audit ......................................................................................................................................... 63
7.17. Audit Dispute ........................................................................................................................... 63
7.18. Confidentiality ......................................................................................................................... 64
7.19. No Other Compensation ......................................................................................................... 64
7.20. No Limitation ........................................................................................................................... 64
7.21. No Refunds ............................................................................................................................... 64
ARTICLE 8 INTELLECTUAL PROPERTY ........................................................................................ 64
8.1. Ownership of Intellectual Property ....................................................................................... 64
8.2. HotSpot Screening Obligation ................................................................................................ 65
8.3. Maintenance and Prosecution of Patents .............................................................................. 65
8.4. Enforcement of IP .................................................................................................................... 69
8.5. Infringement Claims by Third Parties .................................................................................. 71
8.6. Invalidity or Unenforceability Defenses or Actions .............................................................. 73
8.7. Product Trademarks ............................................................................................................... 74
8.8. Inventor's Remuneration ........................................................................................................ 75
8.9. Common Interest ..................................................................................................................... 75
ARTICLE 9 CONFIDENTIALITY AND NON-DISCLOSURE ......................................................... 76
9.1. Product Information................................................................................................................ 76
9.2. Confidentiality Obligations ..................................................................................................... 76
9.3. Permitted Disclosures .............................................................................................................. 77
9.4. Use of Name .............................................................................................................................. 79
9.5. Public Announcements ............................................................................................................ 79
9.6. Publications .............................................................................................................................. 79
9.7. Return of Confidential Information ...................................................................................... 80
9.8. Survival ..................................................................................................................................... 80
ARTICLE 10 REPRESENTATIONS AND WARRANTIES ............................................................... 81
10.1. Mutual Representations and Warranties .............................................................................. 81
10.2. Additional Representations and Warranties of HotSpot ..................................................... 81
10.3. Additional Covenants of HotSpot .......................................................................................... 85
10.4. Debarment and Exclusion ....................................................................................................... 87
10.5. Anti-Bribery and Anti-Corruption Compliance ................................................................... 88
10.6. Bring Down Limitations .......................................................................................................... 88
10.7. DISCLAIMER OF WARRANTIES ...................................................................................... 88
ARTICLE 11 INDEMNITY ..................................................................................................................... 89
11.1. Indemnification of HotSpot .................................................................................................... 89
11.2. Indemnification of AbbVie ..................................................................................................... 89
11.3. Special Indemnity. ................................................................................................................... 90
11.4. Certain Losses .......................................................................................................................... 90
11.5. Notice of Claims ....................................................................................................................... 90
11.6. Control of Defense of Third Party Claims ............................................................................ 90
11.7. Special, Indirect, and Other Losses ....................................................................................... 92
11.8. Insurance. ................................................................................................................................. 92
ARTICLE 12 TERM AND TERMINATION ........................................................................................ 93
12.1. Term.......................................................................................................................................... 93
12.2. Termination for Material Breach .......................................................................................... 93
12.3. Additional Termination Rights by AbbVie ........................................................................... 94
12.4. Termination for Failure or Delay to Obtain Antitrust Clearance ...................................... 94
12.5. Termination for Insolvency .................................................................................................... 94
12.6. Rights in Bankruptcy .............................................................................................................. 95
12.7. Termination in Entirety .......................................................................................................... 95
12.8. AbbVie Additional Remedy for HotSpot Material Breach .................................................. 96
12.9. Termination of Terminated Territory ................................................................................... 97
12.10. Other Effects of Termination ................................................................................................. 99
12.11. Reverse Royalty ..................................................................................................................... 101
12.12. Remedies ................................................................................................................................. 102
12.13. Accrued Rights; Surviving Obligations ............................................................................... 102
ARTICLE 13 MISCELLANEOUS ....................................................................................................... 102
13.1. Force Majeure ........................................................................................................................ 102
13.2. Change in Control of HotSpot .............................................................................................. 103
13.3. Export Control ....................................................................................................................... 104
13.4. Assignment ............................................................................................................................. 104
13.5. Severability ............................................................................................................................. 105
13.6. Governing Law, Jurisdiction and Service ........................................................................... 105
13.7. Dispute Resolution ................................................................................................................. 105
13.8. Notices ..................................................................................................................................... 106
13.9. Entire Agreement; Amendments ......................................................................................... 107
13.10. English Language .................................................................................................................. 107
13.11. Equitable Relief ..................................................................................................................... 107
13.12. Waiver and Non-Exclusion of Remedies ............................................................................. 108
13.13. No Benefit to Third Parties ................................................................................................... 108
13.14. Further Assurance ................................................................................................................. 108
13.15. Relationship of the Parties .................................................................................................... 108
13.16. Performance by Affiliates ..................................................................................................... 108
13.17. Counterparts; Facsimile Execution ..................................................................................... 108
13.18. References .............................................................................................................................. 109
13.19. Schedules ................................................................................................................................ 109
13.20. Construction ........................................................................................................................... 109
SCHEDULES
Schedule 1.57 Corporate Names
Schedule 1.75 Initial Development Plan and Budget
Schedule 1.92 Existing HotSpot Patents
Schedule 1.98 Final Data Package
Schedule 1.119 HotSpot Existing Compounds
Schedule 1.120 HotSpot Existing Mature Program Patents
Schedule 1.239 Stage 1 Information Report
Schedule 1.242 Stage 2 Information Report
Schedule 1.245 Stage 3 Information Report
Schedule 1.248 Stage 4 Information Report
Schedule 3.2.2 Approved Subcontractors
Schedule 8.3.1 Patent Roadmap
Schedule 9.5 Public Announcements
Schedule 10.2 Disclosures to Additional Representations and Warranties of HotSpot
Schedule 13.7.3 ADR Procedures
COLLABORATION AND OPTION TO LICENSE AGREEMENT
This Collaboration and Option to License Agreement (the "Agreement") is made and entered into effective as of December 2, 2022 (the "Effective Date") by and between HotSpot Therapeutics, Inc., a corporation organized under the laws of the State of Delaware ("HotSpot"), and AbbVie Global Enterprises Ltd., a company orga...
RECITALS